IL290006A - Dosing regimen for an IDO inhibitor - Google Patents
Dosing regimen for an IDO inhibitorInfo
- Publication number
- IL290006A IL290006A IL290006A IL29000622A IL290006A IL 290006 A IL290006 A IL 290006A IL 290006 A IL290006 A IL 290006A IL 29000622 A IL29000622 A IL 29000622A IL 290006 A IL290006 A IL 290006A
- Authority
- IL
- Israel
- Prior art keywords
- dosing regimen
- ido inhibitor
- ido
- inhibitor
- regimen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962881518P | 2019-08-01 | 2019-08-01 | |
| PCT/US2020/044533 WO2021022172A1 (en) | 2019-08-01 | 2020-07-31 | A dosing regimen for an ido inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL290006A true IL290006A (en) | 2022-03-01 |
Family
ID=72139706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL290006A IL290006A (en) | 2019-08-01 | 2022-01-20 | Dosing regimen for an IDO inhibitor |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210030869A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4007602A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022543062A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220044527A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114502196A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020319875A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3148776A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL290006A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022001133A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12022550246A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021022172A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1879573T3 (da) | 2005-05-10 | 2013-02-25 | Incyte Corp | Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf |
| CA3012229C (en) | 2008-07-08 | 2020-11-10 | Incyte Holdings Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| EA202191201A1 (ru) | 2018-12-03 | 2022-01-26 | Эдженсис, Инк. | Фармацевтические композиции, включающие конъюгаты анти-191p4d12 антитело-лекарственное средство, и способы их применения |
| US12122848B2 (en) * | 2020-07-09 | 2024-10-22 | The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Compositions and methods for treating fibroids |
| JP2024502005A (ja) * | 2020-12-29 | 2024-01-17 | インサイト・コーポレイション | A2a/a2b阻害剤、pd-1/pd-l1阻害剤、及び抗cd73抗体を含む併用療法 |
| CA3224640A1 (en) | 2021-07-09 | 2023-01-12 | Krishnan SAMPATHKUMAR | Pharmaceutical compositions of a pd-1 antibody and use of the same |
| KR20240042109A (ko) * | 2021-08-13 | 2024-04-01 | 어젠시스 인코포레이티드 | 191P4D12 단백질에 결합하는 항체 약물 접합체[Antibody Drug Conjugate, ADC]로 비근침윤성 방광암[Non-muscle invasive bladder cancer, NMIBC]을 치료하는 방법 |
| WO2026026944A1 (zh) * | 2024-08-02 | 2026-02-05 | 应世生物科技(南京)有限公司 | 新用途 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5156840A (en) | 1982-03-09 | 1992-10-20 | Cytogen Corporation | Amine-containing porphyrin derivatives |
| US5057313A (en) | 1986-02-25 | 1991-10-15 | The Center For Molecular Medicine And Immunology | Diagnostic and therapeutic antibody conjugates |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
| ES2342240T3 (es) | 1998-08-11 | 2010-07-02 | Novartis Ag | Derivados de isoquinolina con actividad que inhibe la angiogenia. |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| CN100391958C (zh) | 2001-09-19 | 2008-06-04 | 安万特医药股份有限公司 | 化合物 |
| PT1441737E (pt) | 2001-10-30 | 2006-12-29 | Dana Farber Cancer Inst Inc | Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3 |
| NZ534069A (en) | 2002-01-22 | 2007-03-30 | Warner Lambert Co | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| AU2004205631A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| DK1639014T3 (da) | 2003-06-13 | 2011-01-17 | Biogen Idec Inc | Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf |
| AU2004266159A1 (en) | 2003-08-22 | 2005-03-03 | Biogen Idec Ma Inc. | Improved antibodies having altered effector function and methods for making the same |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| RU2007123675A (ru) | 2004-11-24 | 2008-12-27 | Новартис АГ (CH) | Комбинации ингибиторов jak |
| AU2008343932B2 (en) | 2007-12-19 | 2013-08-15 | Amgen Inc. | Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors |
| CA3012229C (en) | 2008-07-08 | 2020-11-10 | Incyte Holdings Corporation | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| KR102186969B1 (ko) | 2010-10-25 | 2020-12-04 | 쥐원 쎄라퓨틱스, 인크. | Cdk 억제제 |
| KR101606250B1 (ko) | 2011-03-23 | 2016-03-24 | 암젠 인크 | Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제 |
| EP3744715A1 (en) | 2013-11-08 | 2020-12-02 | Incyte Holdings Corporation | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor |
| PE20231958A1 (es) | 2015-07-30 | 2023-12-06 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
| CN108472245A (zh) * | 2015-11-04 | 2018-08-31 | 因赛特公司 | 用于吲哚胺2,3-双加氧酶抑制及其适应症的药物组合物和方法 |
| MX2018014950A (es) * | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| AU2019205904A1 (en) * | 2018-01-05 | 2020-06-18 | Dicerna Pharmaceuticals, Inc. | Reducing beta-catenin and IDO expression to potentiate immunotherapy |
-
2020
- 2020-07-31 WO PCT/US2020/044533 patent/WO2021022172A1/en not_active Ceased
- 2020-07-31 EP EP20757758.6A patent/EP4007602A1/en not_active Withdrawn
- 2020-07-31 AU AU2020319875A patent/AU2020319875A1/en active Pending
- 2020-07-31 CA CA3148776A patent/CA3148776A1/en active Pending
- 2020-07-31 KR KR1020227006814A patent/KR20220044527A/ko not_active Ceased
- 2020-07-31 PH PH1/2022/550246A patent/PH12022550246A1/en unknown
- 2020-07-31 JP JP2022506474A patent/JP2022543062A/ja active Pending
- 2020-07-31 CN CN202080065914.XA patent/CN114502196A/zh active Pending
- 2020-07-31 US US16/944,953 patent/US20210030869A1/en not_active Abandoned
- 2020-07-31 MX MX2022001133A patent/MX2022001133A/es unknown
-
2022
- 2022-01-20 IL IL290006A patent/IL290006A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020319875A1 (en) | 2022-02-17 |
| PH12022550246A1 (en) | 2023-06-26 |
| EP4007602A1 (en) | 2022-06-08 |
| KR20220044527A (ko) | 2022-04-08 |
| JP2022543062A (ja) | 2022-10-07 |
| CN114502196A (zh) | 2022-05-13 |
| CA3148776A1 (en) | 2021-02-04 |
| MX2022001133A (es) | 2022-04-25 |
| US20210030869A1 (en) | 2021-02-04 |
| WO2021022172A1 (en) | 2021-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289949A (en) | Dosing regimens for oral complement factor d inhibitors | |
| GB201911804D0 (en) | Crypotgraphy using a crypotgraphy state | |
| GB201906536D0 (en) | A carton | |
| CA210281S (en) | Carton | |
| CA188809S (en) | Packaging | |
| ZAA201901817S (en) | Packaging | |
| PT4340842T (pt) | Sotorasib para utilização no tratamento de cancro | |
| SI4058148T1 (sl) | Dozirni režim za sredstva proti BCMA | |
| GB202015090D0 (en) | Corner-protection structure for a case | |
| IL309246A (en) | Dosage regimen for TEAD inhibitor | |
| CA188808S (en) | Packaging | |
| HK40076620A (en) | A dosing regimen for an ido inhibitor | |
| GB201808798D0 (en) | Angle determination for a generator | |
| HK40074182A (en) | Dosing regimen for anti-dll3 agents | |
| GB201916231D0 (en) | Testing a container | |
| GB2590361B (en) | A Carton | |
| GB201911720D0 (en) | A Package | |
| GB201911723D0 (en) | A package | |
| GB2588808B (en) | A jig | |
| GB2590412B (en) | A container | |
| ZA202004674B (en) | A container | |
| HK40081443A (en) | Dosing regimens for a protein kinase c inhibitor | |
| GB201913336D0 (en) | A carton | |
| GB201903335D0 (en) | A sunlounger | |
| CA187189S (en) | Packaging |